Caio Vinicius Suartz

Dr. Caio Vinicius Suartz

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in International braz j urol
Verified
Journal Article
Open access
PDF file
CSCaio Vinicius Suartz
Caio Vinicius Suartz
LMLucas Motta Martinez
Lucas Motta Martinez
MSMarcelo Henrique Lima Silvestre
Marcelo Henrique Lima Silvestre
RLRichard Dobrucki de Lima
Richard Dobrucki de Lima
PBPedro Henrique Souza Brito
Pedro Henrique Souza Brito
LFLeopoldo Alves Ribeiro Filho
Leopoldo Alves Ribeiro Filho
Objective: This systematic review and meta-analysis aim to consolidate current evidence on the diagnosis, epidemiology, and treatment of urachal carcinoma, a rare malignancy with limited data.

6 August 2025 in European Urology Open Science
Verified
Journal Article
Open access
CSCaio Vinicius Suartz
Caio Vinicius Suartz
RLRichard Dobrucki de Lima
Richard Dobrucki de Lima
LALucas Schenk de Almeida
Lucas Schenk de Almeida
BLBruno Liebl
Bruno Liebl
RLRoberto Iglesias Lopes
Roberto Iglesias Lopes
VFVicent Fradet
Vicent Fradet
Immune checkpoint inhibitors (ICIs), alone or with platinum-based chemotherapy, have increasingly been studied as neoadjuvant therapy for muscle-invasive bladder cancer (BC). We sought to evaluate the current evidence about neoadjuvant immunotherapy for BC. In this systematic review, conducted in October 2024, only prospective studies on neoadjuvant immunotherapy for BC were included. Extracted variables encompassed study design, clinical-pathological characteristics, perioperative outcomes, pathological complete response (pCR) rates, overall survival (OS), event-free survival, and immune-related (irAEs) and treatment-related (TRAEs) adverse events. From 726 records, 35 studies met the inclusion criteria. The highest pCR rate observed was 54%, utilizing durvalumab. Perioperative chemoimmunotherapy with durvalumab plus cisplatin/gemcitabine showed greater OS than chemotherapy alone in the NIAGARA trial. The NEMIO trial achieved the highest 12-mo OS rate of 97%, using durvalumab in combination with tremelimumab and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, followed by the AURA trial (95%) and the LCCC1520 trial (91%). At 24 mo, the NEBULA trial reported a 100% OS rate with three doses of atezolizumab, while PrECOG PrE0807 reached and OS rate of 89% with nivolumab and lirilumab. The highest rates of grade 3 and 4 irAEs were reported for nivolumab combined with ipilimumab (54%) and for durvalumab combined with tremelimumab (64%). The most common grade 3/4 irAEs were hepatitis (2–27%), kidney injury (2–100%), and skin rash (1.1–41%). Grade 3/4 TRAEs were comparable between the ICI and chemotherapy groups. Neoadjuvant immunotherapy for BC has shown promising efficacy and a manageable adverse event profile. However, financial toxicity, the absence of predictive biomarkers, and the risk of significant irAEs remain challenges. This study reviewed recent clinical trials that tested immunotherapy before surgery in patients with bladder cancer. The results suggest that a combination of immunotherapy and chemotherapy may improve outcomes and reduce the risk of cancer returning. These findings could help shape future treatment options for patients with muscle-invasive bladder cancer.

2 November 2022 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
LRLeopoldo Ribeiro‐Filho
Leopoldo Ribeiro‐Filho
CSCaio Vinicius Suartz
Caio Vinicius Suartz
NBNatalia D. S. F. Braz
Natalia D. S. F. Braz
MSMatheus Siqueira
Matheus Siqueira
FHFelipe Hirasaki
Felipe Hirasaki
WNWilliam C. Nahas
William C. Nahas

27 April 2025 in Clinics
Verified
Journal Article
Open access
CMCaio Felipe Araujo Matalani
Caio Felipe Araujo Matalani
MCMateus Silva Santos Costa
Mateus Silva Santos Costa
MRMarcelo Ribeiro da Rocha
Marcelo Ribeiro da Rocha
RLRoberto Iglesias Lopes
Roberto Iglesias Lopes
TTThalita Bento Talizin
Thalita Bento Talizin
CSCaio Vinicius Suartz
Caio Vinicius Suartz
To evaluate the comparative outcomes of Minimally Invasive Radical Prostatectomy (MIRP) versus Open Radical Prostatectomy (ORP) to treat localized prostate cancer, using only Randomized Controlled Trials (RCTs) to ensure high-quality evidence. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines, focusing solely on RCTs comparing MIRP (robot-assisted or laparoscopic surgery) and ORP. Literature searches across multiple databases, including Cochrane Library, Medline, Embase, Lilacs, Scopus, Web of Science, NIH, Clinical Trials, and EU Clinical Trials Register, identified studies meeting predefined PICOT criteria. Four RCTs met inclusion criteria ‒ two representing the same cohort of patients ‒ and were analyzed for perioperative, functional, and oncologic outcomes. Quality assessment utilized the ROB-2 tool to gauge the risk of bias. Three RCTs encompassing 1051 patients were analyzed. MIRP demonstrated statistically significant benefits over ORP in terms of reduced perioperative blood loss (Standardized Mean Difference [SMD = -3.058], p = 0.006), lower transfusion rates (Odds Ratio [OR = 0.137]; p = 0.009), and fewer overall complications (OR = 0.465; p = 0001). However, no significant differences were found in long-term oncologic and functional outcomes, including urinary continence and erectile function. Positive surgical margins and additional treatments also did not differ significantly between groups. This systematic review and meta-analysis of RCTs indicated that MIRP offers perioperative advantages over ORP, supporting its role as a safe and effective option for localized prostate cancer.

21 May 2024 in Canadian Urological Association Journal
Verified
Journal Article
Closed access
PDF file
CSCaio Vinicius Suartz
Caio Vinicius Suartz
LMLucas Motta Martinez
Lucas Motta Martinez
MCMaurício Dener Cordeiro
Maurício Dener Cordeiro
HFHunter Ausley Flores
Hunter Ausley Flores
SKSarah Kodama
Sarah Kodama
LRLeopoldo Alves Ribeiro-Filho
Leopoldo Alves Ribeiro-Filho
Introduction: Neoadjuvant cisplatin-based combination chemotherapy (NAC) followed by radical cystectomy is the standard of care for cisplatin-fit patients harboring muscle-invasive bladder cancer (MIBC). Prediction of response to NAC is essential for clinical decision-making regarding alternatives in case of non-response and bladder-sparing in case of complete response. This research aimed to assess the performance of machine learning in predicting therapeutic response following NAC treatment in patients with MIBC. Methods: A systematic review adhering to the PRISMA guidelines was conducted until July 2023. The study integrated articles relating to artificial intelligence and NAC response in MIBC from various databases. The quality of articles was evaluated using the Quality Assessment Tool for Diagnostic Accuracy Studies 2 (QUADAS-2). A meta-analysis was subsequently performed on selected studies to determine the sensitivity and specificity of machine learning algorithms in predicting NAC response. Results: Of 655 articles identified, 12 studies comprising 1523 patients were included, and four studies were eligible for meta-analysis. The sensitivity and specificity of the studies were 0.62 (95% confidence interval [CI] 0.50–0.72) and 0.82 (95% CI 0.72–0.89), respectively, with a heterogeneity score (I2) of 38.5%. The machine learning algorithms used computed tomography, genetic, and anatomopathological data as input and exhibited promising potential for predicting NAC response. Conclusions: Machine-learning algorithms, especially those using computed tomography, genetic, and pathologic data, demonstrate significant potential for predicting NAC response in MIBC. Standardization of methodologic data analysis and response criteria are needed as validation studies.

9 April 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
ADAlexandre Danilovic
Alexandre Danilovic
CSCaio Vinicius Suartz
Caio Vinicius Suartz
FTFabio Cesar Miranda Torricelli
Fabio Cesar Miranda Torricelli
GMGiovanni Scala Marchini
Giovanni Scala Marchini
CBCarlos Batagello
Carlos Batagello
EMEduardo Mazzucchi
Eduardo Mazzucchi